Fluorine-18-fluorocyclopropylhexadecanoic acid

Drug Profile

Fluorine-18-fluorocyclopropylhexadecanoic acid

Alternative Names: 18F-FCPHA; 18F-fluorocyclopropylhexadecanoic acid; Cardiac PET imaging agent - FluoroPharma; CardioPET; FCPHA; Fluorocyclopropylhexadecanoic acid-F-18; trans-9-18F-Fluoro-3,4-methylenehepadecanoic acid

Latest Information Update: 09 Jun 2016

Price : $50

At a glance

  • Originator Harvard Medical School; Massachusetts General Hospital
  • Developer FluoroPharma
  • Class Fatty acids; Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Coronary artery disease

Most Recent Events

  • 06 Jun 2016 Fluorine-18-fluorocyclopropylhexadecanoic acid licensed to Hainan Sinotau Pharmaceutical in China and Canada
  • 31 Aug 2015 Fluorine-18-fluorocyclopropylhexadecanoic acid is still in phase II trials for Coronary artery disease (Diagnosis) in Belgium
  • 01 Dec 2012 Phase-II clinical trials in Diagnostic imaging in Belgium (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top